Passionate about what we do, and having worked together for many years, we have maintained exceptional values within our team, across our unrivalled network of contacts and for our clients.
We are a people business.
Mary has a 20-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies.
She has run several high profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, reverse mergers, as well as numerous follow-on public financings.
Mary has worked with over 100 healthcare clients across Europe and the US including Teva Pharmaceutical, Bayer, Fresenius Medical Care, Kite Pharmaceuticals, UDG Healthcare, Evotec and BioNTech.
Mary has built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company’s IPO and the start-up of several new tech and biotech companies.
Supriya is an experienced communications professional with over 17 years’ of advising clients in financial communications and investor relations, in the UK and overseas. Having worked in both agency and in-house, she has significant expertise in developing and implementing communications strategies to support business and project objectives, and is a media relations specialist with strong entrepreneurial, project and team management skills.
Supriya has implemented global media and investor relations campaigns for clients across healthcare, technology and financial services. She has worked on numerous transactions including fundraisings, M&A and IPOs.
Eva has 20 years’ experience in fund management and company analysis across the global healthcare sector. She lived in New York for 7 years covering the US. She was recently at Schroder Investment management where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in medical devices & supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance.
Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.
Hollie specialises in providing financial and corporate communications support to a wealth of private and public healthcare companies both in the UK and in Europe.
With over 7 years experience, Hollie has managed and implemented successful IR and PR programmes for her clients, providing support on everything from financial calendar work, investor roadshows and analyst briefings, perception studies and event management to support on major strategic deals and transactions including fundraisings, M&A and IPOs. She also provides media relations expertise to her clients, working across print, online and broadcast media.
Dr Niall Kirk
Dr Niall Kirk
Niall has over 20 years’ experience in analyzing and investing in a wide range of healthcare companies, from biotechnology start-ups to pharma, medtech, generic and healthcare service companies. He was at F&C Asset Management managing the global healthcare funds and advising other F&C funds on the healthcare sector. Prior to this he was at Commerzbank as a biotechnology analyst.
He started his career in healthcare consulting specializing in business development between pharmaceutical and biotechnology firms. He went on to build up the due diligence unit, particularly for biotechnology company IPOs on the London market.
Jonathan has over 25 years’ experience in the City as a sellside analyst at SG Warburg/UBS and Redburn, specialising in the pharmaceutical sector. Latterly, at Redburn, he managed the proprietary research service, in-house and for institutional clients.
Jonathan has established and run several companies with a broad range of products and services.
Nick has over 23 years’ of experience advising a wide range of international and UK companies on a broad range of multi-stakeholder communications programmes. Financial market communications is a core strength and he has advised both UK and non-UK listed companies on their communications to both equity and debt investors.
He has helped many companies at key moments of change, whether making their market debut, raising capital (he has helped companies raise more than US$30bn), during transformational acquisitions (he has advised on transactions worth more than US$100bn), or ensuring accurate understanding of the drivers behind their performance. He has particular experience of message development, presentation development, management rehearsal, annual report messaging and drafting, financial reporting, financial media relations preparation and delivery.
Seasoned all-round communication professional and director with a strong strategic and financial profile. Long-time experience in taking responsibility for leading communication roles in crises, international merger & acquisitions, sustainability, Initial Private Offerings, as well as building and leading an integrated communications and investor relations department.
Broad corporate experience as Director Corporate Communications & Investor Relations of Delta Lloyd NV, Amsterdam from 2002 until 2016 (listed in Amsterdam and Brussels). Previously held communications management functions for Corus Group plc (since 2007 part of Tata Steel), in the Netherlands and London and Dutch steel company Koninklijke Hoogovens NV (1998-2001).
Our partner in the USA, Burns McClellan, based in New York
Dedicated exclusively to the life sciences industry, offering a comprehensive approach to public and investor relations.
We are always looking for talented people who can think strategically and work creatively. Whether you’re an established strategic communications practitioner or looking to start your career in investor relations and PR – we want to hear from you.